Use of leflunomide plus TNF-α inhibitors in rheumatoid arthritis

Bibliography

• Fox RI, Herrmann ML, Frangou CG, et al. Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol 1999;93(3):198-208
   PubMed Web of Science ®Google Scholar
• Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999;159(21):2542-50
   PubMed Web of Science ®Google Scholar
• Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 1999;353(9149):259-66
   PubMed Web of Science ®Google Scholar
• Emery P, Breedveld FC, Lemmel EM, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2000;39(6):655-65
   PubMed Web of Science ®Google Scholar
• Kremer J, Genovese M, Cannon GW, et al. Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trial. J Rheumatol 2004;31(8):1521-31
   PubMed Web of Science ®Google Scholar
• Golicki D, Newada M, Lis J, et al. Leflunomide in monotherapy of rheumatoid arthritis: meta-analysis of randomized trials. Pol Arch Med Wewn 2012;122(1-2):22-32
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69(6):964-75
   PubMed Web of Science ®Google Scholar
• Londono J, Santos AM, Santos PI, et al. Therapeutic efficacy and safety of methotrexate + leflunomide in Colombian patients with active rheumatoid arthritis refractory to conventional treatment. Rev Bras Reumatol 2012;52(6):837-45
   PubMedGoogle Scholar
• Kellner H, Bornholdt K, Hein G. Leflunomide in the treatment of patients with early rheumatoid arthritis–results of a prospective non-interventional study. Clin Rheumatol 2010;29(8):913-20
   PubMed Web of Science ®Google Scholar
• Bergner R, Peters L, Schmitt V, Löffler C. Leflunomide in dialysis patients with rheumatoid arthritis–a pharmacokinetic study. Clin Rheumatol 2013;32(2):267-70
   PubMed Web of Science ®Google Scholar
• Yoo HG, Yu HM, Jun JB, et al. Risk factors of severe infections in patients with rheumatoid arthritis treated with leflunomide. Mod Rheumatol 2012; In press
   Google Scholar
• Lee SW, Park HJ, Kim BK, et al. Leflunomide increases the risk of silent liver fibrosis in patients with rheumatoid arthritis receiving methotrexate. Arthritis Res Ther 2012;14(5):R232
   PubMed Web of Science ®Google Scholar
• Murdaca G, Colombo BM, Puppo F. Anti-TNF-alpha inhibitors: a new therapeutic approach for inflammatory immune-mediated diseases: an update upon efficacy and adverse events. Int J Immunopathol Pharmacol 2009;22(3):557-65
   PubMed Web of Science ®Google Scholar
• Murdaca G, Colombo BM, Cagnati P, et al. Update upon efficacy and safety of TNF-alpha inhibitors. Expert Opin Drug Saf 2012;11(1):1-5
   PubMed Web of Science ®Google Scholar
• Murdaca G, Colombo BM, Puppo F. Emerging biological drugs: a new therapeutic approach for Systemic Lupus Erythematosus. An update upon efficacy and adverse events. Autoimmun Rev 2011;11(1):56-60
   PubMed Web of Science ®Google Scholar
• Murdaca G, Colombo BM, Puppo F. Adalimumab for the treatment of immune-mediated diseases: an update on old and recent indications. Drugs Today (Barc) 2011;47(4):277-88
   PubMed Web of Science ®Google Scholar
• Murdaca G, Colombo BM, Barabino G, et al. Anti-tumor necrosis factor-alpha treatment with infliximab for disseminated granuloma annulare. Am J Clin Dermatol 2010;11(6):437-9
   PubMed Web of Science ®Google Scholar
• Puppo F, Murdaca G, Ghio M, Indiveri F. Emerging biologic drugs for the treatment of rheumatoid arthritis. Autoimmun Rev 2005;4(8):537-41
   PubMed Web of Science ®Google Scholar
• Murdaca G, Spanò F, Puppo F. Selective TNF-alpha inhibitor-induced injection site reactions. Expert Opin Drug Saf 2013;12(2):187-93
   PubMed Web of Science ®Google Scholar
• Kalden JR, Nüsslein HG, Wollenhaupt J, et al. Combination treatment with infliximab and leflunomide in patients with active rheumatoid arthritis: safety and efficacy in an open-label clinical trial. Clin Exp Rheumatol 2008;26(5):834-40
   PubMed Web of Science ®Google Scholar
• Kiely PD, Johnson DM. Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open-label study. Rheumatology (Oxford) 2002;41(6):631-7
   PubMed Web of Science ®Google Scholar
• Sokolove J, Strand V, Greenberg JD, et al. CORRONA Investigators. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. Ann Rheum Dis 2010;69(9):1612-17
   PubMed Web of Science ®Google Scholar
• Benucci M, Saviola G, Baiardi P, et al. Efficacy and safety of leflunomide or methotrexate plus subcutaneous tumour necrosis factor-alpha blocking agents in rheumatoid arthritis. Int J Immunopathol Pharmacol 2011;24(1):269-74
   PubMed Web of Science ®Google Scholar
• Minoretti P, Bruno A, Di Vito C, Emanuele E. Leflunomide as an antiatherogenic drug. Med Hypotheses 2007;68(5):1175-6
   PubMed Web of Science ®Google Scholar
• Murdaca G, Spanò F, Cagnati P, Puppo F. Free radicals and endothelial dysfunction: potential positive effects of TNF-alpha inhibitors. Redox Rep 2013; In press
   PubMed Web of Science ®Google Scholar
• Murdaca G, Spanò F, Miglino M, Puppo F. Effects of TNF-alpha inhibitors upon the mechanisms of action of VEGF. Immunotherapy 2013;5(2):113-15
   PubMed Web of Science ®Google Scholar
• Ciprandi G, Murdaca G, Colombo BM, et al. Serum vascular endothelial growth factor in allergic rhinitis and systemic lupus erythematosus. Hum Immunol 2008;69(8):510-12
   PubMed Web of Science ®Google Scholar
• Ciprandi G, Colombo BM, Murdaca G, De Amici M. Serum vascular endothelial growth factor and sublingual immunotherapy. Allergy 2008;63(7):945-6
   PubMed Web of Science ®Google Scholar
• Szekanecz Z, Kerekes G, Soltész P. Vascular effects of biologic agents in RA and spondyloarthropathies. Nat Rev Rheumatol 2009;5(12):677-84
   PubMed Web of Science ®Google Scholar
• Colombo BM, Cacciapaglia F, Puntoni M, et al. Traditional and non traditional risk factors in accelerated atherosclerosis in systemic lupus erythematosus: role of vascular endothelial growth factor (VEGATS Study). Autoimmun Rev 2009;8(4):309-15
   PubMed Web of Science ®Google Scholar
• Colombo BM, Murdaca G, Caiti M, et al. Intima-media thickness: a marker of accelerated atherosclerosis in women with systemic lupus erythematosus. Ann N Y Acad Sci 2007;1108:121-6
   PubMed Web of Science ®Google Scholar
• Murdaca G, Colombo BM, Cagnati P, et al. Endothelial dysfunction in rheumatic autoimmune diseases. Atherosclerosis 2012;224(2):309-17
   PubMed Web of Science ®Google Scholar
• Takemura S, Braun A, Crowson C, et al. Lymphoid neogenesis in rheumatoid synovitis. J Immunol 2001;167:1072-80
   PubMed Web of Science ®Google Scholar
• Murdaca G, Colombo BM, Puppo F. The role of Th17 lymphocytes in the autoimmune and chronic inflammatory diseases. Intern Emerg Med 2011;6(6):487-95
   PubMed Web of Science ®Google Scholar
• Chiang EY, Kolumam GA, Yu X, et al. Targeted depletion of lymphotoxin-alpha-expressing TH1 and TH17 cells inhibits autoimmune disease. Nat Med 2009;15(7):766-73
   PubMed Web of Science ®Google Scholar
• Murdaca G, Colombo BM, Contini P, Puppo F. Determination of lymphotoxin-alpha levels in patients with psoriatic arthritis undergoing etanercept treatment. J Interferon Cytokine Res 2012;32(6):277-9
   PubMed Web of Science ®Google Scholar